Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma will ...
According to one of the authors, additional work is needed to validate findings in a larger prospective study ‘and to apply ...
In a groundbreaking development for cancer treatment, Caribou Biosciences announced promising results from its off-the-shelf CAR-T therapy in patients with advanced B-cell lymphoma. This innovative ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, ...
Abcuro, Inc., a late-stage clinical biotechnology company developing potential first-in-class immunotherapies for the benefit of people living with debilitating and progressive rare autoimmune ...
Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...
When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...
A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event. About ...
Community-based CAR T-cell therapy improves access, reducing travel burdens and hospital admissions for patients with blood ...
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell ...
From relapse to remission: Groundbreaking therapy gives Non-Hodgkin’s Lymphoma patients renewed hope
Doctors are turning to a groundbreaking new therapy; one that’s not only giving patients more healthy years, but in some ...
The integration of Bruton tyrosine kinase (BTK) inhibitors into first-line treatment regimens, in combination with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback